Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

Civacir® (Civacir) - Prophylaxis hepatitis C reinfection
Tregalizumab (BT-061) - Plaque psoriasis
Tregalizumab (BT-061) - Rheumatoid arthritis
IgM Concentrate (BT-086) - Severe bacterial infection
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine (BT-062) - Solid tumors
(BT-063) - Systemic lupus erythematosus
Fibrinogen (BT-524) - Congenital and acquired fibrinogen deficiency
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

Press releases

Biotest Phase IIb study of Tregalizumab (BT-061) in mo...

24.04.2015, News

Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - potential one time effect of up to - EUR 30 million - No safety ... [More]

Biotest Phase IIb study of Tregalizumab (BT-061) in mod...

24.04.2015, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - ... [More]

Biotest presents new clinical and preclinical results o...

23.04.2015, News

Biotest presents new clinical and preclinical results of Civacir(R) at The 50th International Liver Congress 2015 in Vienna - Preliminary clinical results suggest that Civacir(R) reduces the ... [More]

Biotest proves effective protection from Hepatitis B vi...

23.04.2015, News

Biotest proves effective protection from Hepatitis B virus reinfection after liver transplantation in "ZEUS" study with subcutaneous hepatitis B immunoglobulin Zutectra(R) - The ... [More]

Biotest announces the opening of a plasma collection fa...

13.04.2015, News

Biotest announces the opening of a plasma collection facility in Conway, Arkansas, US and the relocation of it's plasma collection Facility in San Antonio, Texas, US - Total number of plasma ... [More]

Biotest increases sales by 16.2%

24.03.2015, News

Biotest increases sales by 16.2% - Earnings before interest and tax (EBIT) at EUR 53.4 million - Expansion project "Biotest Next level" in timeline and budget - Share split with the ... [More]

Biotest AG: Biotest proposes capital increase from capi...

17.03.2015, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest AG: Biotest proposes capital increase from capital funds and share split to General Meeting - Proposed capital ... [More]

DGAP-AFR: Biotest AG: Announcement according to Article...

10.03.2015, AFR

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 24, 2015 Date of disclosure / English: ... [More]

Release according to Article 26, Section 1 of the WpHG ...

23.02.2015, PVR

On February 20, 2015, Deka Investment GmbH, Frankfurt am Main, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, ... [More]

Biotest increases revenues significantly by 16.2%

13.02.2015, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest increases revenues significantly by 16.2% Dreieich, 13. February 2015. According to preliminary and unaudited figures, ... [More]

Biotest AG:

09.02.2015, News

Biotest opens another plasma collection center in the US - Biotest continues strengthening global plasma collection with a second plasma collection center in Jacksonville, North Caroline, ... [More]

Publication according to § 26 paragraph. 1 WpHG with t...

02.02.2015, PVR

Universal-Investment-Gesellschaft mbH, 60486 Frankfurt, Germany has informed us according to Article 21, Section 1 of the WpHG that via shares its Voting Rights on Biotest AG, Dreieich, Germany, ... [More]

Encouraging Efficacy of Indatuximab Ravtansine (BT-062)...

09.12.2014, News

Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone - New data from combination therapy study presented at 56th ... [More]

Further preclinical studies emphasise the potential of ...

24.10.2014, News

Further preclinical studies emphasise the potential of Indatuximab Ravtansine (BT-062) in solid tumours - Antibody-drug conjugate shows high efficacy in an animal model in the treatment of ... [More]

Search at Biotest - company rejects allegation

15.10.2014, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Search at Biotest - company rejects allegations Dreieich, October 15, 2014. The Frankfurt Public Prosecution Office today once ... [More]

Search at Biotest - company rejects allegations

15.10.2014, News

Search at Biotest - company rejects allegations - Accusations absolutely incomprehensible for Biotest AG - Proposal for clarification not accepted by public prosecutor Dreieich, October 15, ... [More]

Biotest completes recruitment in Phase IIb study (TREAT...

09.09.2014, News

Biotest completes recruitment in Phase IIb study (TREAT 2b) of Tregalizumab (BT-061) in patients with rheumatoid arthritis - Biotest's largest and most complex clinical study is running ... [More]

Biotest increases revenues by 8,5%

11.08.2014, News

Biotest increases revenues by 8,5% - EBIT increase by 2,3% - Good Progress in the R&D pipeline - Revised outlook Dreieich, August 11, 2014. The Biotest Group was again able to ... [More]

Outlook revised

11.08.2014, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Outlook revised Dreieich, August 11, 2014. The Management Board revises its outlook. A sales increase of 7% and an operating ... [More]

Dr. Bernhard Ehmer to become new CEO of Biotest AG

09.07.2014, Adhoc

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Dr. Bernhard Ehmer to become new CEO of Biotest AG Dreieich, 9 July 2014 - The Supervisory Board of Biotest AG, in its meeting ... [More]

Careers

Careers

Passionate to help us save lives?

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialigue with the financial community.